Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia

Bone Marrow Transplant. 2002 Jun;29(11):927-30. doi: 10.1038/sj.bmt.1703558.

Abstract

A pediatric patient with very early meningeal relapse of his CD34(+) CD133(-) pre-B-ALL was transplanted with 2.5 x 10(6)/kg CD133 selected autologous progenitor cells. Enrichment of CD133(+) cells resulted in a purity of 92.3 +/- 3.5% CD133(+). Hematopoietic engraftment with >1.0 x 10(9)/l neutrophils and >50 x 10(9)/l platelets was reached within 13 and 24 days, respectively. At a follow-up of 11(1/2) months after autologous transplantation, the patient is in complete remission. To our knowledge, the successful transplantation with a CD133 selected graft is the first one to be reported worldwide. CD133 selected cells may serve as an alternative in the case of CD34(+) malignancy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Acute Disease
  • Antigens, CD
  • Child
  • Glycoproteins*
  • Graft Survival
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukapheresis / methods
  • Male
  • Peptides*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Remission Induction
  • Salvage Therapy
  • Transplantation, Autologous / methods

Substances

  • AC133 Antigen
  • Antigens, CD
  • Glycoproteins
  • PROM1 protein, human
  • Peptides